Lamichhane N, Melas N, Bergqvist V, Ekholm NP, et al. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Dig Dis Sci 2024 Apr 18. doi: 10.1007/s10620-024-08422.
PMID: 38637457